Innovent Biologics, Inc. 1801
HKEX · Hong Kong SAR China · Health Technology
HKD 98.05+2.15 (+2.24%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Investing.com -- Bernstein has identified several China-based biopharmaceutical companies positioned to benefit from evolving drug development capabilities, with a focus on integrated platforms and service providers that support AI-enabled research and development workflows.
Innovent Biologics has delivered a very large 3 year share price return, which puts the current valuation firmly under the microscope for anyone focused on cash flows. With the stock recently closing at HK$95.90, the key issue is how that price lines up with the cash Innovent Biologics is expected to generate over time. The share price gain of 153.4% over the past 3 years means a lot of optimism is already baked in, so the cash flow story now has to do the heavy lifting. Fresh clinical data...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentatio
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.